BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 33165928)

  • 1. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy: unlocking the potentials of cell-free DNA.
    Chu D; Park BH
    Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Interest of Circulating Tumor DNA in Oncology.
    Franczak C; Filhine-Tressarieu P; Broséus J; Gilson P; Merlin JL; Harlé A
    Arch Med Res; 2018 Jul; 49(5):297-305. PubMed ID: 30414710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
    Yang M; Forbes ME; Bitting RL; O'Neill SS; Chou PC; Topaloglu U; Miller LD; Hawkins GA; Grant SC; DeYoung BR; Petty WJ; Chen K; Pasche BC; Zhang W
    Ann Oncol; 2018 Feb; 29(2):311-323. PubMed ID: 29216340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy: Emergence of an Alternative Cancer Detection Method.
    Law EW; Settell ML; Kurani SS; Eckert EC; Liu MC; Greenberg-Worisek AJ
    Clin Transl Sci; 2020 Sep; 13(5):845-847. PubMed ID: 32233063
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy for cancer screening, diagnosis, and treatment.
    Smania MA
    J Am Assoc Nurse Pract; 2020 Jan; 32(1):5-7. PubMed ID: 31913212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
    Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
    Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer.
    Roy D; Tiirikainen M
    Trends Cancer; 2020 Feb; 6(2):78-81. PubMed ID: 32061307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
    Liu SC
    World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Standard Practice in Liquid Biopsy: Selective Venous Sampling.
    Damascelli B; Tichà V; Repetti E; Dorji T
    J Vasc Interv Radiol; 2021 May; 32(5):668-671. PubMed ID: 33621662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.
    Boonstra PA; Wind TT; van Kruchten M; Schuuring E; Hospers GAP; van der Wekken AJ; de Groot DJ; Schröder CP; Fehrmann RSN; Reyners AKL
    Cancer Metastasis Rev; 2020 Sep; 39(3):999-1013. PubMed ID: 32367253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.